Latest Regulatory News

Southern Palladium fast-tracks development at its Bengwenyama PGM Project, advancing drilling and infrastructure plans while securing key regulatory approvals.

Estrella Resources reports strong progress at its Werumata Limestone Project with over 70% of drilling completed, alongside promising manganese intersections at Ira Manganese Prospect. Infrastructure and feasibility studies are underway, positioning the company as a first mover in Timor-Leste’s emerging mining sector.

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Somerset Minerals confirms robust high-grade copper mineralisation at its Jura North prospect within the Coppermine Project, Nunavut, with plans for an aggressive 2026 drilling campaign and regional exploration across its extensive landholding.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Aura Energy has secured a new exploration permit in Sweden, adjacent to its existing Häggån project, positioning the company to deepen its stake in a globally significant polymetallic resource area.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

Sunshine Metals Limited will lift its trading suspension on 24 November 2025 following a key Supreme Court ruling. Investors await details on the court outcome that triggered the suspension.

Atomic Eagle Ltd, formerly known as Tombador Iron Limited, will have its trading suspension lifted and be reinstated to quotation on the ASX starting 24 November 2025 after meeting key compliance requirements.

The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.

Critica Limited has completed the first tranche of its $8 million placement, issuing over 203 million shares to accelerate development at its Jupiter rare earths project. The second tranche awaits shareholder approval in January 2026.

Rox Resources has successfully completed the first tranche of a $200 million capital raise, issuing 188.7 million shares at 35 cents each. The second tranche, worth $134 million, awaits shareholder approval in December.